Figure 1 provides an example of this strategy where tumour and TME ROIs were able to be identified within the same tumour core. Of all the samples collected, comparisons from the same patient could be made between eight TME–NAT pairs, 14 NAT–tumour pairs, and 18 tumour–TME pairs. Figure 2 provides an overview of the tumour and immune ROI selection, as well as representative expression profiles for a number of associated markers. Here, BRD2 is linked to neoplasm.